Med. praxi. 2025;22(4):259-262 | DOI: 10.36290/med.2025.050

Where is the treatment of atherosclerosis heading?

prof. MUDr. Otto Mayer, CSc.
II. interní klinika UK LF a FN Plzeň

The prevention of atherosclerotic vascular diseases remains crucial for global population health. Therefore, it is essential that we have a sufficient number of drug classes with proven benefits for patients in this area. However, it is equally important to consistently use all these new treatment possibilities in real clinical practice and actively pursue to achieve defined treatment goals for individual risk factors.

Keywords: cardiovascular disease, secondary prevention, lipids.

Received: May 23, 2025; Accepted: June 9, 2025; Published: September 29, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Mayer O. Where is the treatment of atherosclerosis heading? Med. praxi. 2025;22(4):259-262. doi: 10.36290/med.2025.050.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42:3227-337. Go to original source...
    2. Vorlickova P, Mayer O, Bruthans J, et al. The changes in achievement of target LDL-cholesterol levels between 2006 and 2017 in Czech patients with chronic coronary heart disease. Cor Et Vasa. 2019;61:E20-E6. Go to original source...
    3. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. Jama. 1999;282:2340-6. Go to original source...
    4. Cannon CP, Steinberg BA, Murphy SA, et al. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. Journal of the American College of Cardiology. 2006;48:438-45. Go to original source...
    5. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. The New England journal of medicine. 2017;376:1713-1722. Go to original source...
    6. Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. The New England journal of medicine. 2018;379:2097-107. Go to original source...
    7. Landmesser U, Koenig W, Leiter LA, et al. Inclisiran in patients with prior myocardial infarction: A post hoc pooled analysis of the ORION-10 and ORION-11 Phase 3 randomised trials. Atherosclerosis. 2023;386:117354. Go to original source...
    8. Cordero A, Santos-Gallego CG, Fácila L, et al. Estimation of the major cardiovascular events prevention with Inclisiran. Atherosclerosis. 2020;313:76-80. Go to original source...
    9. Taheri H, Filion KB, Windle SB, et al. Cholesteryl Ester Transfer Protein Inhibitors and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Cardiology. 2020;145:236-50. Go to original source...
    10. Nicholls SJ, Nelson AJ, Ditmarsch M, et al. Obicetrapib on top of maximally tolerated lipid-modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN. American heart journal. 2024;274:32-45. Go to original source...
    11. Nicholls SJ, Nelson AJ, Ditmarsch M, et al. Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk. The New England journal of medicine. 2025;393(1):51-61. Go to original source...
    12. Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. The New England journal of medicine. 2023;388:1353-64. Go to original source...
    13. Berg K. A NEW SERUM TYPE SYSTEM IN MAN--THE LP SYSTEM. Acta Pathol Microbiol Scand. 1963;59:369-82. Go to original source...
    14. Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31:2844-53. Go to original source...
    15. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, et al. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. Jama. 2009;301:2331-9. Go to original source...
    16. Willeit P, Ridker PM, Nestel PJ, et al. Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. Lancet. 2018;392:1311-20. Go to original source...
    17. Lamina C. Mendelian Randomization: Principles and its usage in Lp(a) research. Atherosclerosis. 2022;349:36-41. Go to original source...
    18. O'Donoghue ML, Rosenson RS, Gencer B, et al. Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease. The New England journal of medicine. 2022;387:1855-64. Go to original source...
    19. Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, et al, Steinhagen-Thiessen E, et al. Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. The New England journal of medicine. 2020;382:244-55. Go to original source...
    20. Packard CJ. Remnants, LDL, and the Quantification of Lipoprotein-Associated Risk in Atherosclerotic Cardiovascular Disease. Curr Atheroscler Rep. 2022;24:133-42. Go to original source...
    21. Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. The New England journal of medicine. 2010;362:1563-74. Go to original source...
    22. Bergmark BA, Marston NA, Prohaska TA, et al. Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk. The New England journal of medicine. 2024;390:1770-80. Go to original source...
    23. Jones A, Peers K, Wierzbicki AS, et al. Long-term effects of volanesorsen on triglycerides and pancreatitis in patients with familial chylomicronaemia syndrome (FCS) in the UK Early Access to Medicines Scheme (EAMS). Atherosclerosis. 2023;375:67-74. Go to original source...
    24. Ballantyne CM, Vasas S, Azizad M, et al. Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia. The New England journal of medicine. 2024;391:899-912. Go to original source...
    25. Rosenson RS, Burgess LJ, Ebenbichler CF, et al. Longer-Term Efficacy and Safety of Evinacumab in Patients With Refractory Hypercholesterolemia. JAMA Cardiol. 2023;8:1070-6. Go to original source...
    26. Zimerman A, Wiviott SD, Park JG, et al. Reductions in remnant cholesterol and VLDL cholesterol through inhibition of ANGPTL3 protein synthesis: an analysis from the TRANSLATE-TIMI 70 trial. European journal of preventive cardiology. 2024;31:1216-23. Go to original source...
    27. Das Pradhan A, Glynn RJ, Fruchart JC, et al. Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk. The New England journal of medicine. 2022;387:1923-34. Go to original source...

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.